Invst LLC Makes New $466,000 Investment in Novo Nordisk A/S $NVO

Key Points

• Invst LLC made a new investment of $466,000 in Novo Nordisk A/S during the 1st quarter, acquiring 6,707 shares of the company.
• Research analysts have recently issued mixed ratings for Novo Nordisk A/S, with price objectives ranging from $57.00 to $105.00 and an average target price of $81.00.
• Novo Nordisk A/S reported EPS of $0.97 for the last quarter, exceeding analyst expectations of $0.93, while also experiencing a dividend yield of 240.0%.

Invst LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,707 shares of the company's stock, valued at approximately $466,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Anchor Investment Management LLC lifted its position in Novo Nordisk A/S by 1.1% during the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock worth $944,000 after acquiring an additional 150 shares in the last quarter. Xponance Inc. lifted its position in Novo Nordisk A/S by 5.0% during the 1st quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after acquiring an additional 158 shares in the last quarter. Foster Dykema Cabot & Partners LLC increased its holdings in Novo Nordisk A/S by 3.8% during the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock worth $319,000 after purchasing an additional 166 shares during the last quarter. 180 Wealth Advisors LLC increased its holdings in Novo Nordisk A/S by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock worth $348,000 after purchasing an additional 173 shares during the last quarter. Finally, Beacon Financial Group increased its holdings in Novo Nordisk A/S by 6.5% during the 1st quarter. Beacon Financial Group now owns 2,884 shares of the company's stock worth $200,000 after purchasing an additional 177 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NVO shares. TD Cowen dropped their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Dbs Bank upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Friday, August 22nd. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 20th. Finally, HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a report on Thursday, July 31st. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Trading Up 1.2%

Shares of NVO stock opened at $54.94 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $138.22. The stock has a fifty day moving average of $57.96 and a two-hundred day moving average of $66.49. The firm has a market capitalization of $245.31 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's payout ratio is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.